Look WHO’s Talking! Vaccine Scientists Confirm Major Safety Problems

"The bombshell video footage, published by Del Bigtree’s The Highwire, captures a series of statements—profoundly unsettling in their matter-of-factness—made by professionals who, in early December, attended the World Health Organization’s (WHO’s) two-day Global Vaccine Safety Summit. The summit’s aims were to 'take stock of [the] accomplishments' of WHO’s Global Advisory Committee on Vaccine Safety (GACVS) and work toward finalizing the agency’s Global Vaccine Safety Blueprint 2.0 strategy 2021-2030. Attendees included GACVS members (past and present), vaccine program managers, regulatory authorities, drug safety staff, 'and representatives of UN agencies, academic institutions, umbrella organizations of pharmaceutical companies, technical partners, industry representatives and funding agencies.'

What did this crème de la crème of the vaccine establishment say during their two-day powwow? Among other discussion points, attendees admitted that:

• Vaccines can be fatal.
• The design of safety studies makes it difficult to spot problems.
• Safety monitoring is inadequate.
• Vaccine adjuvants increase risk...

Flawed safety studies

Several WHO summit speakers described the lack of 'good science' and the inability of vaccine clinical trials to provide meaningful information about safety and risk. Describing the 'tyranny of small numbers' and the 'relatively small sample sizes' typical of vaccine clinical trials, for example, Dr. David Kaslow characterized these features as 'a real conundrum' but offered no suggestions for solving it...

Dr. Marion Gruber, Director of the U.S. Food and Drug Administration’s (FDA’s) Office of Vaccines Research and Review, with 'over 20 years of experience in the regulatory review and approval of... vaccines and related biologics,' unblushingly agreed that vaccine pre-licensure clinical trials 'may not be powered enough' (meaning they are too small to detect statistically significant effects) and that the generally inadequate follow-up of trial participants 'complicates safety evaluation'...

Inadequate safety monitoring

Dr. Robert Chen is a 30-year veteran of the U.S. Centers for Disease Control and Prevention (CDC) and currently directs the Task Force for Global Health’s Brighton Collaboration... [A]t the WHO summit, he declared that safety monitoring databases remain incapable of 'teasing out' vital information such as details about manufacturers and lot numbers. Dr. Swaminathan chimed in that 'we really don’t have very good safety monitoring systems in many countries'...

Risky adjuvants

... Friede, who held “several senior management positions in the vaccine industry" prior to moving to WHO, added:

I give courses every year on 'How do you develop vaccines?' 'How do you make vaccines?' And the first lesson is, while you’re making your vaccine, if you can avoid using an adjuvant, please do so.  Lesson two is, if you’re going to use an adjuvant, use one that has a history of safety. And lesson three is, if you’re not going to do that, think very carefully.

Friede also noted that the 'primary concern' with vaccine adjuvants is systemic adverse events: 'The major health concern which we are seeing are accusations of long term . . . effects.'"